Cardiol Therapeutics Inc. lost $0.28 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Cardiol Therapeutics Inc. has filed alongside them.
FY2025 annual
EPS (Diluted)-$0.28
YoYn/m
5Y CAGRn/m
Source SEC Filings (40-F/6-K)Latest period FY2025, ended Dec 31, 2025ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
CRDL EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Cardiol Therapeutics Inc.'s diluted earnings per share in fiscal year 2025?
Cardiol Therapeutics Inc. lost $0.28 per diluted share in fiscal year 2025.
How fast is Cardiol Therapeutics Inc.'s diluted earnings per share growing?
Cardiol Therapeutics Inc. (CRDL) reported a loss of $0.35 per diluted share in fiscal year 2024 and a loss of $0.28 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
How has Cardiol Therapeutics Inc.'s diluted earnings per share changed over the years?
Across the 6 fiscal years this page covers, Cardiol Therapeutics Inc. (CRDL) diluted earnings per share went from -$0.54 in fiscal year 2020 to -$0.28 in fiscal year 2025.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Cardiol Therapeutics Inc. (CRDL) reported on that line in every period on record.
